NasdaqGM:MGTA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Magenta Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MGTA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-8.7%

MGTA

-1.0%

US Biotechs

-1.2%

US Market


1 Year Return

-30.6%

MGTA

39.3%

US Biotechs

19.5%

US Market

Return vs Industry: MGTA underperformed the US Biotechs industry which returned 39.3% over the past year.

Return vs Market: MGTA underperformed the US Market which returned 19.5% over the past year.


Shareholder returns

MGTAIndustryMarket
7 Day-8.7%-1.0%-1.2%
30 Day-9.3%2.8%5.8%
90 Day-11.4%-2.8%8.1%
1 Year-30.6%-30.6%41.8%39.3%22.3%19.5%
3 Yearn/a20.0%14.0%43.6%34.0%
5 Yearn/a21.2%12.5%87.3%66.1%

Price Volatility Vs. Market

How volatile is Magenta Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Magenta Therapeutics undervalued compared to its fair value and its price relative to the market?

1.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MGTA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MGTA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MGTA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MGTA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MGTA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MGTA is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Magenta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-8.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGTA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MGTA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MGTA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MGTA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if MGTA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MGTA is forecast to be unprofitable in 3 years.


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Magenta Therapeutics performed over the past 5 years?

-37.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MGTA is currently unprofitable.

Growing Profit Margin: MGTA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MGTA is unprofitable, and losses have increased over the past 5 years at a rate of 37.9% per year.

Accelerating Growth: Unable to compare MGTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MGTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: MGTA has a negative Return on Equity (-47.91%), as it is currently unprofitable.


Next Steps

Financial Health

How is Magenta Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: MGTA's short term assets ($179.9M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: MGTA's short term assets ($179.9M) exceed its long term liabilities ($6.4M).


Debt to Equity History and Analysis

Debt Level: MGTA is debt free.

Reducing Debt: MGTA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MGTA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MGTA has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 38.2% each year.


Next Steps

Dividend

What is Magenta Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MGTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MGTA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MGTA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MGTA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MGTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Jason Gardner (49 yo)

4.67yrs

Tenure

US$1,651,001

Compensation

Dr. Jason Gardner, Ph.D., D. Phil., is a Cofounder of Magenta Therapeutics, Inc. and has been its Chief Executive Officer and President since February 2016. Dr. Gardner joined Atlas Venture in November 201 ...


CEO Compensation Analysis

Compensation vs Market: Jason's total compensation ($USD1.65M) is about average for companies of similar size in the US market ($USD1.91M).

Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jason Gardner
Co-Founder4.67yrsUS$1.65m1.87%
$ 6.3m
John Davis
Head of Research & Development and Chief Medical Officer2.67yrsUS$913.52k0.017%
$ 58.1k
Cindy Driscoll
Interim Principal Financial & Accounting Officerno datano datano data
Lisa Olson
Chief Scientific Officer0.083yrno datano data
Zoran Zdraveski
Chief Legal Officer3.5yrsno data0.28%
$ 931.1k
Kristen Stants
Chief People Officer0.67yrno datano data
Christina Isacson
Chief Business Officerno dataUS$2.28m0.17%
$ 586.5k
Catherine Monaghan
Head of Clinical Development Operations2.58yrsno datano data
Jan Pinkas
Senior VP & Head of Translational Sciences1yrno datano data
Li Malmberg
Senior VP & Head of Manufacturing0.67yrno datano data
Kevin Johnson
Senior VP & Head of Regulatory and Quality0.083yrno datano data
Alison Lawton
Board Advisor2.5yrsUS$4.38kno data

1.8yrs

Average Tenure

50yo

Average Age

Experienced Management: MGTA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jason Gardner
Co-Founder4.67yrsUS$1.65m1.87%
$ 6.3m
Michael Bonney
Independent Chairman4yrsUS$236.86k0.14%
$ 457.4k
Thomas Daniel
Independent Director4yrsUS$203.95k0.21%
$ 713.5k
Alexis Borsey
Independent Director5.33yrsUS$206.95kno data
Bruce Booth
Independent Director4.67yrsUS$201.45kno data
Anne McGeorge
Independent Director1.33yrsUS$377.27kno data
Robert Negrin
Member of Scientific Advisory Boardno datano datano data
John DiPersio
Member of Scientific Advisory Boardno datano datano data
Jeffrey Albers
Independent Director3.25yrsUS$204.36k0.0086%
$ 29.1k
Luigi Naldini
Member of Scientific Advisory Boardno datano datano data
David Scadden
Independent Chair of Scientific Advisory Board & Director3.92yrsUS$297.95k0.47%
$ 1.6m
Alan Tyndall
Member of Scientific Advisory Boardno datano datano data

4.0yrs

Average Tenure

59yo

Average Age

Experienced Board: MGTA's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.3%.


Top Shareholders

Company Information

Magenta Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Magenta Therapeutics, Inc.
  • Ticker: MGTA
  • Exchange: NasdaqGM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$337.291m
  • Shares outstanding: 48.18m
  • Website: https://www.magentatx.com

Number of Employees


Location

  • Magenta Therapeutics, Inc.
  • 100 Technology Square
  • 5th Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MGTANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2018
3MTDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2018

Biography

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 01:28
End of Day Share Price2020/10/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.